Wednesday, March 19, 2025 3:13:45 PM
https://fintel.io/so/us/amrn/sarissa-capital-management-lp
13F summary, bottom of page. End of 2022. 19M shares sold out of his LP to multiple sub funds ahead of the proxy. He listed the active sub funds in the proxy... a list of friends, off shore accounts, holding accounts, etc. This activity routed through his prime broker for sure as it was discussed at the time on this board with people thinking MS picked up 19M shares to help fight his proxy. No, it was those same shares getting distributed. Q3 2023, 5M shares sold back to his LP from his sub funds. Q1 2024, 14M shares back to his LP. All the while he's claimed he "never sold a share". Share prices at those transaction dates were all well below his initial buy in and transaction gets booked at that share price. You don't get to just move shares at book value to another tax entity. He's been offsetting gains, taxes, etc.
Also, why do such a convoluted holding structure? Well, all his sub funds can do what they want. Buy, sell, short, etc without reporting as they're exempt from 13F&D requirements. Meanwhile, the LP just reports his total "controlling interest" of the total shares as long as the LP doesnt break a 1% move in outstanding shares.
13F summary, bottom of page. End of 2022. 19M shares sold out of his LP to multiple sub funds ahead of the proxy. He listed the active sub funds in the proxy... a list of friends, off shore accounts, holding accounts, etc. This activity routed through his prime broker for sure as it was discussed at the time on this board with people thinking MS picked up 19M shares to help fight his proxy. No, it was those same shares getting distributed. Q3 2023, 5M shares sold back to his LP from his sub funds. Q1 2024, 14M shares back to his LP. All the while he's claimed he "never sold a share". Share prices at those transaction dates were all well below his initial buy in and transaction gets booked at that share price. You don't get to just move shares at book value to another tax entity. He's been offsetting gains, taxes, etc.
Also, why do such a convoluted holding structure? Well, all his sub funds can do what they want. Buy, sell, short, etc without reporting as they're exempt from 13F&D requirements. Meanwhile, the LP just reports his total "controlling interest" of the total shares as long as the LP doesnt break a 1% move in outstanding shares.
Recent AMRN News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:10 PM
